Provider review
Noom Med tirzepatide review
What Noom Med charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of Noom Med's tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What is distinctive about this programme?
A dose cap is not a discount
This is the clearest instance in our dataset of a pricing structure that requires explanation rather than comparison. Noom Med's $199 semaglutide programme is capped at a 0.6 mg maximum dose. The STEP trials that established semaglutide's weight-management efficacy used 2.4 mg.
A capped programme is not a cheaper version of the same treatment. It is a lower-dose treatment with a correspondingly smaller expected effect, and it should not appear in the same price ranking as full-titration programmes. Noom's own full-titration programme is $279, which is the figure that belongs in a like-for-like comparison.
We have kept the capped programme out of our cheapest-by-definition table for exactly this reason.
Introductory pricing and quarterly billing
The first month is $149 for tirzepatide against $299 ongoing. Introductory rates are excluded from every ranking on this site.
Quarterly billing sits between month-to-month and prepaid: less commitment than twelve months, less flexibility than monthly, and a three-month exposure if you stop.
Where the full programmes sit
At $279 semaglutide and $299 tirzepatide, Noom's full-titration programmes are in the upper band of the compounded market. Brand Zepbound is $299 direct from LillyDirect, and the approved oral orforglipron is $149 — both FDA-approved products at or below Noom's compounded tirzepatide price.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $199 | Reported |
| Tirzepatide injectable | $299 | Reported |
Where does this provider hold up?
- Publishes both a capped and a full-titration option rather than only the cheaper one
- Quarterly billing is a middle path between monthly and annual commitment
- Established consumer platform with an existing behavioural programme
Where does this provider fall short?
- The $199 programme is capped at 0.6 mg, well below the trial dose
- Full-titration pricing is in the upper band of the compounded market
- Compounded tirzepatide at $299 matches brand Zepbound's manufacturer-direct starter price
- First-month rates are introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $199/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
What does this provider charge, all in?
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Noom Med | prepaid | compounded injectable | — | $199 | — | $199 | Commitment tier | Reported | 2026-07-06 |
| Noom Med | prepaid | compounded injectable | — | $299 | — | $299 | Commitment tier | Reported | 2026-07-06 |
How does this provider sit against the market?
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Trimi | $125 | Verified |
| Fifty 410 | $133 | Verified |
| Found | $169 | Reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| NexLife (opens nexlife.us in a new tab) | $190 | Verified |
| NexLife | $195 | Verified |
| NexLife | $215 | Verified |
| Trimi | $235 | Verified |
| Shed | $245 | Reported |
| Mochi Health | $278 | Verified |
| Enhance.MD | $280 | Reported |
| Noom Med | $299 | Reported |
| TrimRx | $349 | Reported |
| bmiMD | $399 | Reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not?
Where does this provider hold up?
- nothing verified yet
Where does this provider fall short?
- nothing verified yet
Which states does this provider serve?
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Who assesses you, and how?
Which pharmacy fills the prescription?
Billing, cancellation and support
What changed, and when?
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How does this provider compare to the category?
Once enough providers are scored, this section reports where Noom Med sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered No public price |
| Clinical oversight and care continuity | 20 pts | — | Not answered No public price |
| State access and operational reliability | 10 pts | — | Not answered No public price |
| Cancellation, billing and support transparency | 10 pts | — | Not answered No public price |
A dash means no figure held. How we grade evidence.
Frequently asked questions
Is Noom Med the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Privacy PolicyCore & Trust
- Open GLP-1 Data and Evidence LibraryData
- Oak Longevity Tirzepatide ReviewProviders
Related coverage
- NexLife Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- How to Start Semaglutide: What the Label Says and What to Expect
- Hunger Comes Back Before My Next Dose: What That Usually Means
- GLP-1 Insurance Coverage: What Plans Actually Do, and How to Find Out Fast
- Appealing a GLP-1 Denial: The Four Levels and What Wins at Each
- When Your Plan Drops GLP-1 Coverage: What Changes and What You Can Do
- GLP-1 Prior Authorization: What Plans Ask For and How to Prepare
Semaglutide Ranked. “Noom Med Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/providers/noom-med/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.